Antinuclear antibody detection in the clinical diagnosis of diffuse connective tissue disease
-
摘要:
目的通过抗核抗体谱检测结果对弥漫性结缔组织病患者临床诊断进行评价。 方法回顾分析246例弥漫性结缔组织病和160例非弥漫性结缔组织病住院患者自身抗体检测结果。 结果在各种弥漫性结缔组织病中抗核抗体谱阳性检出率间差异有统计学意义,在系统性红斑狼疮患者中,抗dsDNA抗体阳性率为44.1%,抗Sm抗体阳性率为47%;在混合性结缔组织病中抗UIRNP抗体阳性率达96.4%;在干燥综合征患者中抗SSA和抗SSB抗体阳性率为68.2%和59.1%;在系统性硬化病患者中抗Scl-70抗体阳性率为41.4%;重叠综合征抗dsDNA、抗Sm、抗UIRNP、抗SSA抗体的阳性率为45.4%、18.2%、45.4%、18.2%。 结论抗核抗体谱检测对各种弥漫性结缔组织病有重要的鉴别诊断意义。 Abstract:ObjectiveTo evaluate the clinical diagnosis of diffuse connective tissue disease patients by antinuclear antibody test Results. MethodMethods a retrospective analysis of 246 cases of diffuse connective tissue diseases and 160 cases of non diffuse connective tissue disease detection in hospitalized patients with autoantibody. Result In a variety of diffuse connective tissue disease antinuclear antibody positive rate between the difference has statistical significance, in systemic lupus erythematosus patients, the positive rate of anti dsDNA antibody was 44.1%, the positive rate of anti Sm antibody positive rate was 47%; in mixed connective tissue disease in anti UIRNP antibody was 96.4% in patients with Sjogren syndrome; syndrome of anti SSA and anti SSB antibody positive rate was 68.2% and 59.1%; in patients with systemic sclerosis in anti Scl-70 antibody positive rate was 41.4%; overlap syndrome, anti dsDNA, anti Sm, anti UIRNP, anti SSA antibody positive rate was 45.4%, 18.2%, 45.4%, 18.2%. ConclusionThere are important in the differential diagnosis of antinuclear antibody spectrum detection of diffuse connective tissue disease. -
Key words:
- diffuse connective tissue disease /
- anti nuclear antibody
-
表 1 弥漫性结缔组织病患者与对照组ANA抗体谱阳性率比较(n, %)
疾病 n 抗dsDNA抗体 抗组蛋白抗体 抗Sm抗体 抗UIRNP抗体 抗SSA抗体 抗SSB抗体 抗Scl-70抗体 抗CENP-B抗体 抗J0-1抗体 SLE 34 15(44.1) 6(17.6) 16(47) 14(41.2) 11(32.4) 5(14.7) 0 3(8.8) 0 RA 29 2(6.9) 2(6.9) 0 3(10.3) 4(13.8) 1(3.5) 0 1(3.5) 2(6.9) MCTD 28 7(25) 4(14.3) 3(10.7) 27(96.4) 5(17.9) 0 0 0 0 PSS 87 0 0 0 0 3(3.5) 2(2.3) 36(41.4) 12(13.8) 0 DM/PM 35 2(5.7) 0 0 3(8.6) 6(17.10) 0 0 2(5.7) 11(31.4) SS 22 0 0 0 0 15(68.2) 13(59.1) 0 0 0 OLs 11 5(45.4) 2(18.2) 5(45.4) 2(18.2) 1(9) 0 0 0 0 对照组 160 2(1.3) 2(1.3) 2(1.3) 1(0.6) 7(4.4) 4(2.5) 1(0.6) 2(1.3) 0 χ2 1380.745 51.631 107.916 156.12 90.673 202.076 21.372 21.631 7.818 P < 0.05 < 0.05 < 0.05 < 0.05 < 0.05 < 0.05 < 0.05 < 0.05 < 0.05 -
[1] 王洪武, 刘又宁, 朴哲龙, 等.结缔组织病重叠综合征37例临床分析[J].临床内科杂志, 2001, 18(5): 369-71. http://www.cnki.com.cn/Article/CJFDTOTAL-LCLZ200105023.htm [2] 马东来, 张少静, (德)斯特克.自身抗体及免疫荧光模式[M].北京科学出版社, 2000: 32-8. [3] 叶应妩, 申子瑜.全国临床检验操作规程[M].南京:东南大学出版社, 2006: 655-66. [4] 邓安梅, 仲人前, 施笑梅, 等.自身免疫病患者可抽提核抗体谱与体液免疫的关系[J].中华医学检验杂志, 1999, 22(5): 42-5. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHYJ199905015.htm [5] 叶任高, 陆再英.内科学.[M] 6版.北京:人民卫生出版社, 2004: 933-6. [6] Steen VD. Clinical manifestations of systemic sclerosis[J]. Semin Cutan Med Surg, 1998, 17(1): 48-54. doi: 10.1016/S1085-5629(98)80062-X [7] Sulli A, Soldano S, Pizzorni C, et al. Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis[J]. J Rheumatol, 2009, 36(6): 1235-9. doi: 10.3899/jrheum.081030 [8] 杨海, 梁宗夏, 张慧娟, 等.抗Scl-70抗体检测与临床应用[J].中国免疫学杂志, 2014, 30(4): 533-4. http://d.wanfangdata.com.cn/Periodical/zgmyxzz201404025 [9] Koenig M, Dieude M, Senecal JL. Predictive value of antinuclear autoantibodies: The lessons of the systemic sclerosis autoantibodies [J]. Autoimmun Rev, 2008, 7(8, SI): 588-93. doi: 10.1016/j.autrev.2008.06.010 [10] Bussone G, Berezne A, Pestre V, et al. The scleroderma kidney: progress in risk factors, therapy, and prevention[J]. Curr Rheumatol Rep, 2011, 13(1): 37-43. doi: 10.1007/s11926-010-0145-7 [11] 冀春梅, 王振明, 马居凤.抗核抗体谱检测在自身免疫性疾病中的意义[J].实用医技杂志, 2008, 15(5): 583-4. http://d.wanfangdata.com.cn/Periodical/syyjzz200805032
点击查看大图
表(1)
计量
- 文章访问数: 751
- HTML全文浏览量: 228
- PDF下载量: 2
- 被引次数: 0